Context Therapeutics Inc
NASDAQ:CNTX 3:59:19 PM EDT
Products
Context Therapeutics' Clinical Partner Stemline Therapeutics Receives FDA Approval Of Orserdu
Published: 01/31/2023 13:50 GMT
Context Therapeutics Inc (CNTX) - Context Therapeutics’ Clinical Partner Stemline Therapeutics, a Subsidiary of Menarini Group Receives FDA Approval of Orserdu™ (elacestrant) in Er+, Her2-, Esr1-mutated Breast Cancer.
Context Therapeutics - Orserdu is Being Evaluated in Combination With Context's Ona-xr in Ongoing Elona Trial.
Context Therapeutics - Orserdu is Being Evaluated in Combination With Context's Ona-xr in Ongoing Elona Trial.